Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China · Delayed Price · Currency is CNY 17.42
+0.35 (2.05%)
Jul 31, 2026, 3:00 PM CST
Nanjing Vazyme Biotech Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,414 | 1,378 | 1,378 | 1,286 | 3,569 | 1,869 |
Revenue Growth | 3.84% | -0.00% | 7.15% | -63.97% | 91.00% | 19.44% |
Gross Profit Gross Profit Growth | 950.2 | 920.21 | 940.43 | 771.1 | 2,176 | 1,479 |
Operating Income Operating Income Growth | -98.8 | -111.66 | -112.85 | -271.53 | 850.23 | 729.91 |
Net Income Net Income Growth | -14.34 | -16.61 | -18.09 | -70.96 | 594.25 | 678.29 |
Earnings Per Share EPS Growth | -0.03 | -0.03 | -0.04 | -0.14 | 1.15 | 1.44 |
EPS Growth | - | - | - | - | -20.32% | -19.04% |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
Research and Experimental Development Research and Experimental Development Growth | 1,170 |
Pharmaceutical Manufacturing Pharmaceutical Manufacturing Growth | 202.94 |
Total Total Growth | 1,373 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 2,940 | 2,854 | 2,656 | 3,481 | 3,264 | 3,454 |
Total Debt Total Debt Growth | 1,007 | 842.44 | 751.71 | 1,287 | 458.14 | 91.18 |
Net Cash (Debt) Net Cash Growth | 1,933 | 2,012 | 1,905 | 2,194 | 2,806 | 3,362 |
Net Cash Growth | 6.39% | 5.62% | -13.19% | -21.81% | -16.56% | 230.91% |
Net Cash Per Share Net Cash Per Share Growth | 3.52 | 3.73 | 4.05 | 4.28 | 5.41 | 7.13 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 209.68 | 233.16 | -9.68 | 152.99 | 735.17 | 616.8 |
Capital Expenditures CapEx Growth | -41.82 | -47.39 | -74.9 | -232.9 | -962.86 | -261.96 |
Free Cash Flow Free Cash Flow Growth | 167.86 | 185.77 | -84.58 | -79.91 | -227.69 | 354.84 |
Free Cash Flow Growth | - | - | - | - | - | -45.49% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 67.22% | 66.78% | 68.25% | 59.96% | 60.98% | 79.13% |
Operating Margin | -6.99% | -8.10% | -8.19% | -21.12% | 23.82% | 39.06% |
Pretax Margin | -2.65% | -2.74% | -4.23% | -9.00% | 17.07% | 40.91% |
Profit Margin | -1.01% | -1.21% | -1.31% | -5.52% | 16.65% | 36.30% |
FCF Margin | 11.88% | 13.48% | -6.14% | -6.21% | -6.38% | 18.99% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.385 | 0.385 | 0.139 | 0.077 | 0.962 | 0.300 |
Dividend Per Share Growth | 261.12% | 177.69% | 80.10% | -92.00% | 220.50% | - |
Dividend Yield | 2.21% | 2.57% | 0.84% | 0.33% | 2.54% | 0.40% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 35.77 | 62.51 |
Forward PE | 84.40 | 74.61 | 43.68 | 48.03 | 23.21 | 43.93 |
P/FCF Ratio | 53.65 | 42.86 | - | - | - | 119.49 |
PS Ratio | 6.37 | 5.78 | 6.40 | 9.96 | 5.96 | 22.69 |